KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Doravirine/Islatravir (100/0.75 mg) Once-Daily Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide as Initial HIV-1 Treatment: 48-Week Results From a Phase 3, Randomized, Controlled, Double-Blind, Noninferiority Trial.

Jürgen K Rockstroh, Roger Paredes, Pedro Cahn, Jean-Michel Molina, Simiso M Sokhela, Federico Hinestrosa, Sheetal Kassim, Douglas Cunningham, Jade Ghosn, Johannes R Bogner, Hiroyuki Gatanaga, Ernest Asante-Appiah, Ying Zhang, Uchechukwu Nwoke, Stephanie O Klopfer, Karen Eves, Kathleen Squires, Todd Correll, Michelle C Fox, Mary L Pisculli

Clin Infect Dis 81(2) 322-332

PMID40079835
PMCIDPMC12448626
DOI10.1093/cid/ciaf077
发表日期2025-03-13
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:Graphical Abstract:AI 判定为 other;Figure 1.:AI 判定为 flow diagram;Figure 2.:森林图/亚组分析图;Figure 3.:AI 判定为 other。
摘要

摘要

BACKGROUND: Doravirine/islatravir is an investigational regimen that is being studied for human immunodeficiency virus type 1 (HIV-1) treatment. METHODS: In this phase 3, double-blind, double-dummy trial (ClinicalTrials.gov NCT04233879), previously untreated adults with HIV-1 were randomized (1:1) and stratified by HIV-1 RNA (≤/>100 000 copies/mL) and CD4 count (</≥200 cells/µL) to doravirine/islatravir (100/0.75 mg) or bictegravir/emtricitabine/tenofovir alafenamide (50/200/25 mg) orally once-daily (primary endpoint: percentage of participants with HIV-1 RNA <50 copies/mL at week 48; US Food and Drug Administration snapshot, 10% noninferiority margin). RESULTS: Overall, 597 participants were treated; enrollment stopped early due to decreases in CD4 and lymphocyte counts observed in other islatravir studies. Doravirine/islatravir was noninferior to bictegravir/emtricitabine/tenofovir alafenamide: 265 of 298 (88.9%) versus 264 of 299 (88.3%) had HIV-1 RNA <50 copies/mL (difference, 0.5%; 95% confidence interval [CI]: -4.7, 5.6). Mean change from baseline in CD4 count was +182 and +234 cells/µL (difference, -50; 95% CI: -79, -21) with doravirine/islatravir versus bictegravir/emtricitabine/tenofovir alafenamide. Mean change in lymphocyte count was 0.01 and 0.21 × 109/L (difference, -0.20; 95% CI: -0.30, -0.10). Adverse events (AEs) occurred in 90.6% and 87.3% of participants, with coronavirus disease 2019 being most common (14.1%, 16.4%). Treatment-related AEs were similar (28.9%, 25.8%). AEs that led to discontinuations were higher with doravirine/islatravir (8.7%, 3.7%) due to protocol-specified criteria that required discontinuation for decreased CD4 and lymphocyte counts. CONCLUSIONS: Doravirine/islatravir (100/0.75 mg) once-daily was noninferior to bictegravir/emtricitabine/tenofovir alafenamide through week 48 for initial HIV-1 treatment. Due to decreases in CD4 and lymphocyte counts, development of this dose of doravirine/islatravir was stopped. CLINICAL TRIALS REGISTRATION: NCT04233879.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Graphical AbstractThis graphical abstract is also available at Tidbit: https://tidbitapp.io/institutional-portal/clinical-infectious-diseases/tidbits/doravirine-islatravir-100-0-75-mg-once-daily-compared-to-bictegravir-emtricitabine-tenofovir-alafenamide-as-initial-hiv-1-treatment-48-week-results-from-a-phase-3-randomized-controlled-double-blind-non-inferiority-trial/update
非 KM Figure
Figure 1.Trial profile. a Participants could have 1 or more reasons for exclusion. b Full analysis set included all randomized participants who received at least 1 dose of study intervention (study drug and placebo) and had baseline measurement for those analyses that required baseline measurements. b Per-protocol set included all participants in the full analysis set who did not have any major protocol violations that could impact the assessment of efficacy, including violation of key entry criteria. Abbreviations: BIC, bictegravir; DOR, doravirine; FTC, emtricitabine; HIV-1, human immunodeficiency virus type 1; ISL, islatravir; TAF, tenofovir alafenamide.
非 KM Figure
Figure 2.Summary of HIV-1 RNA <50 copies/mL by subgroup at week 48 in the full analysis set. a The 95% confidence intervals for the between-group differences in percent response were calculated using the unstratified Miettinen and Nurminen method. The treatment difference 95% CIs were calculated if there were at least 10 participants in each treatment group for each subgroup. b Seventeen participants in the DOR/ISL group and 19 participants in the BIC/FTC/TAF group did not have virologic data in the week 48 window. c Ten participants in the DOR/ISL group and 3 participants in the BIC/FTC/TAF group did not have virologic data in the week 48 window. Abbreviations: BIC, bictegravir; CI, confidence interval; DOR, doravirine; FTC, emtricitabine; HIV-1, human immunodeficiency virus type 1; ISL, islatravir; TAF, tenofovir alafenamide.
非 KM Figure
Figure 3.Plain language summary.
非 KM Figure